Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELINDA
2016-002966-29Phase 3Active
- Sponsor
- Novartis
- Start
- Aug 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in mature B-cell lymphoma and diffuse large B-cell lymphoma (DLBCL) comparing Tisagenlecleucel treatment strategy with Standard of care treatment strategy (2 arms). Primary endpoint: Event-free survival. Started Aug 2018; status: active.
02
Drugs
tisagenlecleucel
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2016-002966-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002966-29.